Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Avigan Filed for COVID-19 in Japan: Fujifilm
Fujifilm Toyama Chemical filed its antiviral Avigan (favipiravir) on October 16 to add a new indication for the treatment of COVID-19, the Fujifilm subsidiary said the same day. The submission seeks an additional indication and dosage pertaining to COVID-19 for…
To read the full story
Related Article
- Advisory Panel Shelves Decision on Avigan, Says No Clear Efficacy Shown for COVID-19
December 22, 2020
- Avigan’s COVID-19 Use Up for PAFSC Review on December 21
December 17, 2020
- Avigan to Come Up for PAFSC Review This Month
December 16, 2020
- (Update) Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
- Avigan Hits Primary Goal for Novel Coronavirus, Filing Eyed in October: Fujifilm
September 24, 2020
- Fujifilm’s Avigan COVID-19 Data Won’t Be Fully Ready until 1 Month from Now
August 21, 2020
- Fujifilm-Sponsored Avigan Trial to Complete Enrollment on Aug. 16
August 12, 2020
- Avigan Fails to Hit Statistical Significance in COVID-19 Trial: Fujita Health Univ.
July 13, 2020
- Fujifilm Inks Global Avigan Deal with Dr. Reddy’s, Global Response Aid
July 2, 2020
- Fujifilm’s Avigan COVID-19 Trial Might Continue into July
June 9, 2020
- Most Mild COVID-19 Patients Recovered on Avigan, but Careful Interpretations Needed for Single-Arm Study: Interim Report
May 27, 2020
- Japan Drops May-End Goal for Avigan’s COVID-19 Approval
May 27, 2020
- Fujifilm Launches Avigan Trial with Completion Eyed in June; Sanofi Too to Test Kevzara in Japan
April 1, 2020
BUSINESS
- M3’s MR-kun Hit by Data Breach, Pharma Staff and Doctors Exposed
October 16, 2026
- Santen Hits 93% Weekly AI Adoption in R&D, Digitizes Truckload of Research Records
October 16, 2026
- Medley Reports Cyberattack, Patient Data at Risk at Up to 787 Facilities
October 16, 2026
- Takeda’s TAK-881 Shaves 56 Minutes Off Infusion Time vs HyQvia
October 16, 2026
- UCB Japan Recalls Cimzia Over Needle Retraction Defect
October 16, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…